Biomarker monitoring for early treatment

Researcher:
Associate Prof. Yoav Shechtman | Biomedical Engineering

Categories:

Medical Devices | Physics and Electro-Optics

The Technology

BiomarkerFlow is a diagnostic platform that enables rapid, multiplexed detection of biomarkers through advanced computational microscopy and microfluidics. It provides a breakthrough alternative to conventional immunoassays, such as ELISA and ECLIA, by offering faster, more scalable, and cost-effective analysis with minimal sample preparation requirements. The technology is designed to operate at clinically relevant sensitivity – achieving a detection limit of 70 pg/mL using less than 50 μL of sample – and delivers results in under an hour, making it suitable for clinical applications that could benefit from continuous, real-time monitoring of protein-based biomarkers.

Advantages

• Rapid and simple sample processing for time-sensitive clinical workflows.
• Multiplexing capability for simultaneous detection of multiple biomarkers.
• Cost-effective and scalable for both centralized labs and bedside testing.
• Applicable to diverse clinical and research needs.

Applications and opportunities

• Transplantation and Cell Therapy Monitoring – for early detection of cytokine dynamics and immune dysregulation during and after treatment, supporting predictive interventions. Examples include early detection of CAR-T-associated toxicities and Graft-versus-Host Disease (GVHD).
• Allergy Monitoring and Management – Detecting and tracking IgE and inflammatory markers to monitor allergy status, prevent severe reactions, and personalize desensitization protocols.
• Hormone Replacement Therapy (HRT) – Monitoring of hormonal biomarkers (e.g., estrogen, testosterone) to tailor and adjust HRT regimens for optimal therapeutic benefit.

arrow Business Development Contacts
Shikma Litmanovitz
Director of Business Development, Physical Science